These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 31564531)

  • 1. Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative.
    Kalapara AA; Verbeek JFM; Nieboer D; Fahey M; Gnanapragasam V; Van Hemelrijck M; Lee LS; Bangma CH; Steyerberg EW; Harkin T; Helleman J; Roobol MJ; Frydenberg M;
    Eur Urol Oncol; 2020 Feb; 3(1):80-91. PubMed ID: 31564531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS-JAPAN).
    Kato T; Matsumoto R; Yokomizo A; Tohi Y; Fukuhara H; Fujii Y; Mori K; Sato T; Inokuchi J; Hashine K; Sakamoto S; Kinoshita H; Inoue K; Tanikawa T; Utsumi T; Goto T; Hara I; Okuno H; Kakehi Y; Sugimoto M
    BJU Int; 2024 Jun; ():. PubMed ID: 38886979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate MRI and artificial intelligence during active surveillance: should we jump on the bandwagon?
    Bozgo V; Roest C; van Oort I; Yakar D; Huisman H; de Rooij M
    Eur Radiol; 2024 Jun; ():. PubMed ID: 38937295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active surveillance: a review of risk-based, dynamic monitoring.
    Nieboer D; Tomer A; Rizopoulos D; Roobol MJ; Steyerberg EW
    Transl Androl Urol; 2018 Feb; 7(1):106-115. PubMed ID: 29594025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy.
    Diaz GM; Webb LT; Rabil MJ; Lokeshwar SD; Choksi AU; Leapman MS; Sprenkle PC
    Curr Urol Rep; 2024 Jun; ():. PubMed ID: 38896314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer-A Report of a Movember International Consensus Meeting.
    Boesen L
    Eur Urol; 2023 Nov; 84(5):515-516. PubMed ID: 37479533
    [No Abstract]   [Full Text] [Related]  

  • 7. Value of a confirmatory re-biopsy as part of a modern risk stratified cancer surveillance programme for early prostate cancer.
    Gabb H; Gnanapragasam VJ
    BJUI Compass; 2024 Jul; 5(7):662-664. PubMed ID: 39022658
    [No Abstract]   [Full Text] [Related]  

  • 8. Active surveillance in all cases of screen-detected prostate cancer.
    Takahashi T
    BJU Int; 2024 Jul; 134(1):136. PubMed ID: 38504623
    [No Abstract]   [Full Text] [Related]  

  • 9. Heterogeneity in active surveillance protocols worldwide.
    Loeb S; Carter HB; Schwartz M; Fagerlin A; Braithwaite RS; Lepor H
    Rev Urol; 2014; 16(4):202-3. PubMed ID: 25548550
    [No Abstract]   [Full Text] [Related]  

  • 10. Treating Prostate Cancer at Any Stage: New technology and better treatment protocols are improving the outlook for patients.
    Garnick MB
    Sci Am; 2024 May; 330(5):66. PubMed ID: 39017191
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience.
    Carlsson S; Benfante N; Alvim R; Sjoberg DD; Vickers A; Reuter VE; Fine SW; Vargas HA; Wiseman M; Mamoor M; Ehdaie B; Laudone V; Scardino P; Eastham J; Touijer K
    J Urol; 2020 Jun; 203(6):1122-1127. PubMed ID: 31868556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can the Use of Serial Multiparametric Magnetic Resonance Imaging During Active Surveillance of Prostate Cancer Avoid the Need for Prostate Biopsies?-A Systematic Diagnostic Test Accuracy Review.
    Hettiarachchi D; Geraghty R; Rice P; Sachdeva A; Nambiar A; Johnson M; Gujadhur R; Mcneill M; Haslam P; Soomro N; Zeeshan Hameed BM; Somani B; Veeratterapillay R; Rai BP
    Eur Urol Oncol; 2021 Jun; 4(3):426-436. PubMed ID: 32972894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.
    Tosoian JJ; Mamawala M; Epstein JI; Landis P; Macura KJ; Simopoulos DN; Carter HB; Gorin MA
    Eur Urol; 2020 Jun; 77(6):675-682. PubMed ID: 31918957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study.
    Stavrinides V; Giganti F; Trock B; Punwani S; Allen C; Kirkham A; Freeman A; Haider A; Ball R; McCartan N; Whitaker H; Orczyk C; Emberton M; Moore CM
    Eur Urol; 2020 Sep; 78(3):443-451. PubMed ID: 32360049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up.
    Klotz L; Pond G; Loblaw A; Sugar L; Moussa M; Berman D; Van der Kwast T; Vesprini D; Milot L; Kebabdjian M; Fleshner N; Ghai S; Chin J; Haider M
    Eur Urol; 2020 Mar; 77(3):311-317. PubMed ID: 31708295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort.
    Giganti F; Stabile A; Stavrinides V; Osinibi E; Retter A; Orczyk C; Panebianco V; Trock BJ; Freeman A; Haider A; Punwani S; Allen C; Kirkham A; Emberton M; Moore CM
    Eur Radiol; 2021 Mar; 31(3):1644-1655. PubMed ID: 33000302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.
    Hoffman KE; Penson DF; Zhao Z; Huang LC; Conwill R; Laviana AA; Joyce DD; Luckenbaugh AN; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Koyama T; Barocas DA
    JAMA; 2020 Jan; 323(2):149-163. PubMed ID: 31935027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance.
    Tomer A; Nieboer D; Roobol MJ; Bjartell A; Steyerberg EW; Rizopoulos D;
    BJU Int; 2021 Jan; 127(1):96-107. PubMed ID: 32531869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.
    Schenk JM; Newcomb LF; Zheng Y; Faino AV; Zhu K; Nyame YA; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW
    J Urol; 2020 Apr; 203(4):727-733. PubMed ID: 31651227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer.
    Chu CE; Lonergan PE; Washington SL; Cowan JE; Shinohara K; Westphalen AC; Carroll PR; Cooperberg MR
    Eur Urol; 2020 Oct; 78(4):515-517. PubMed ID: 32631744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.